Corcept Therapeutics (CORT)
NASDAQ:CORT
Want to see CORT full AI Analyst Report?
CORT Stock Chart & Stats
$46.16
$0.08(0.16%)
At close: 4:00 PM EST
$46.16
$0.08(0.16%)
Day’s Range― - ―
52-Week Range$28.66 - $91.00
Previous CloseN/A
Volume78.39K
Average Volume (3M)1.16M
Market Cap
$6.46B
Enterprise Value$6.37B
Total Cash (Recent Filing)$338.18M
Total Debt (Recent Filing)$9.64M
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Aug 05, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.45
Shares Outstanding107,351,590
10 Day Avg. Volume1,199,904
30 Day Avg. Volume1,156,017
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)5.58
Price to Sales (P/S)4.75
P/FCF Ratio25.49
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue8.28
Enterprise Value/Gross Profit8.42
Enterprise Value/Ebitda-937.23
Forecast
1Y Price Target
$86.25Price Target Upside86.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.5
Revenue Forecast (FY)$957.43M
Bulls Say, Bears Say
Bulls Say
Clinical Evidence CommunicationA full ROSELLA study presentation with complete efficacy, safety, and subgroup analyses will provide clinicians and payers with detailed data to inform adoption and reimbursement discussions.
Commercial ReadinessManagement's plan for a dedicated oncology sales force supports commercial launch capacity and could accelerate relacorilant uptake in oncology markets.
Regulatory ApprovalRegulatory approval of relacorilant for certain women's cancers validates cortisol modulation as an effective treatment mechanism and establishes the company's first commercial oncology product, supporting business diversification.
Bears Say
Generic Competition And Legal RiskA court ruling that reduces the ability to block generic entrants combined with strong uptake of an authorized generic increases the risk of price erosion and market share loss for the branded franchise.
Product Concentration RiskKorlym is the company's only revenue-generating product, leaving the company heavily dependent on its commercial performance and vulnerable to demand or pricing shocks.
Supply Chain And DistributionRepeated distribution failures and specialty pharmacy capacity constraints disrupted prescription fulfillment and could continue to constrain Korlym sales unless supply channels fully stabilize.
Corcept Therapeutics News
CORT FAQ
What was Corcept Therapeutics’s price range in the past 12 months?
Corcept Therapeutics lowest stock price was $28.66 and its highest was $91.00 in the past 12 months.
What is Corcept Therapeutics’s market cap?
Corcept Therapeutics’s market cap is $6.46B.
When is Corcept Therapeutics’s upcoming earnings report date?
Corcept Therapeutics’s upcoming earnings report date is Aug 05, 2026 which is in 72 days.
How were Corcept Therapeutics’s earnings last quarter?
Corcept Therapeutics released its earnings results on Apr 30, 2026. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.11 by -$0.19.
Is Corcept Therapeutics overvalued?
According to Wall Street analysts Corcept Therapeutics’s price is currently Undervalued.
Does Corcept Therapeutics pay dividends?
Corcept Therapeutics does not currently pay dividends.
What is Corcept Therapeutics’s EPS estimate?
Corcept Therapeutics’s EPS estimate is 0.01.
How many shares outstanding does Corcept Therapeutics have?
Corcept Therapeutics has 107,351,590 shares outstanding.
What happened to Corcept Therapeutics’s price movement after its last earnings report?
Corcept Therapeutics reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.11. Following the earnings report the stock price went up 10.533%.
Which hedge fund is a major shareholder of Corcept Therapeutics?
Currently, no hedge funds are holding shares in CORT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corcept Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$86.25 (86.85% Upside)
$86.25 (86.85% Upside)
Blogger Sentiment
Bullish
CORT Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 127.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.85%
12-Months-Change
Fundamentals
Return on Equity
7.50%
Trailing 12-Months
Asset Growth
-3.73%
Trailing 12-Months
Company Description
Corcept Therapeutics
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
CORT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive momentum driven by major clinical and regulatory milestones (Lifyorli FDA approval with a significant survival benefit, landmark CATALYST and MOMENTUM findings that broaden the addressable market, robust patient and prescriber growth, raised 2026 guidance, and compelling ALS and MASH data). Near-term negatives include a Q1 earnings swing to a net loss, temporary revenue headwinds from insurance reauthorizations and a pharmacy-transition backlog, and tolerability-related discontinuations in DAZALS that require mitigation. On balance, the company demonstrated durable commercial traction, an expanding pipeline with high-impact results, and clear plans to address operational issues, leading to a favorable outlook.View all CORT earnings summariesCORT Stock 12 Month Forecast
Average Price Target
$86.25
▲(86.85% Upside)
Technical Analysis
Jazz Pharmaceuticals
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
Legend Biotech
―
Ownership Overview
11.74% Insiders
17.13% Mutual Funds
16.28% Other Institutional Investors
33.43% Public Companies and
Individual Investors